LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Buy” by Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $69.17.

LIVN has been the subject of a number of recent research reports. Robert W. Baird boosted their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, The Goldman Sachs Group began coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Driehaus Capital Management LLC increased its holdings in shares of LivaNova by 64.7% during the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after acquiring an additional 213,749 shares in the last quarter. Perceptive Advisors LLC increased its stake in LivaNova by 48.5% during the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after purchasing an additional 145,000 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in LivaNova in the second quarter worth about $16,614,000. Price T Rowe Associates Inc. MD raised its holdings in LivaNova by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after buying an additional 1,980 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of LivaNova in the second quarter worth approximately $1,103,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Down 0.4 %

NASDAQ:LIVN opened at $52.29 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a one year low of $42.75 and a one year high of $64.47. The company has a market cap of $2.84 billion, a PE ratio of 124.50 and a beta of 1.01. The firm has a 50-day moving average of $52.29 and a 200-day moving average of $52.03.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.